New Hampshire Training Cohort

Slides:



Advertisements
Similar presentations
Contact Evaluation Your name Institution/organization Meeting Date International Standards 18, 19.
Advertisements

ISTC Training Modules 2008 Your name Institution/organization Meeting Date.
June 2004 HITCH Training Slide Set #3 Special Considerations in Antiretroviral Therapy.
MiMOSA Training 1. Opening 2. TB WRx and the 2007 DS Forms 3. Data entry and report generation for the new DS forms 4. Mission settings for DS Forms 5.
TREATMENT Coagulopathy of Liver Failure. Fresh Frozen Plasma – Most effective way to correct hemostasis in patients with liver failure – Infusion (5-10mL/kg)
Washington State Department of Health April 14, 2010 Washington State Cohort Review 2009 trends & 1 st quarter.
Cardiovascular outcome in patients with dysglycemia with daily supplementation of n-3 fatty acids 1 ORIGIN trial (Outcome Reduction with an Initial Glargine.
Integrated Monitoring and Evaluation of HIV Programs in Malawi Dr Andreas Jahn 1,2 1 Dept. for HIV and AIDS, MOH, Malawi 2 I-TECH Malawi.
Group II Treatment regimens, hospitalization. DOT provision, outcome definitions, management of adverse drug reactions.
1 Identifying Cases of MDR-TB Session 3. USAID TB CARE II PROJECT Old WHO recommendations RegimenIndications 4HREZ/2HR (Category I) New cases 2SHREZ/1HREZ/5HRE.
Development of extensive drug resistance in Multi-Drug resistant tuberculosis patients MSF anti-TB programmes in Abkhazia and Uzbekistan Authors: Cathy.
TB Seminar 2014 Agenda and issues in NTP M&E System ARUN GAUTAM, CHIEF, PME SECTION, NTC.
Monitoring and Evaluation Frameworks   What is an M&E Framework?   Why do we use M&E Frameworks?   How do we develop M&E Frameworks? MEASURE Evaluation.
Tuberculosis Follow up Care PA Department of Health Role Maxine Kopiec Community Health Nursing Supervisor April 24, 2015.
Status of Revised National Tuberculosis Control Program (RNTCP) in India Dr Jitendra.
experience from Lesotho
Figure 1. Number of Tuberculosis Cases: California, California Department of Public Health, Tuberculosis Control Branch Number of Tuberculosis.
Action Plan Good Health Situation of Population in Capital of Myanmar Yangon Division By DR MYA THIDA AYE.
Monitoring and Evaluation Module 12 – March 2010.
The Cohort Review Process The Cohort Review Process Kim Field RN, MSN WA State DOH Tuberculosis Program.
TB Control Program County of San Diego Challenges: Cross border Continuity of TB Care Response:CureTBUS/Mexico Tuberculosis Referral and Information Program.
Tuberculosis Treatment Completion Among Persons Incarcerated at Diagnosis, U.S. TB Surveillance System, 1999–2008 Kiren Mitruka, MD, MPH (presented on.
TB 101 Part II Brenda Mayes, R. N. March TREATMENT TB DISEASE MDR XDR LATENT TB INFECTION.
Progress of the Singapore TB Elimination Programme (STEP)
Elements of the Cohort Review Approach Harvey L. Marx, Jr. Lisa Schutzenhofer TB Program Controller TB Program Manager.
V IRGINIA C OHORT D ATA – 5 YEAR TRENDS AFTER 4 YEARS OF LOCAL COHORT REVIEW Virginia achievement on National TB Indicators for the past 5 years – where.
Tuberculosis in the United States National Tuberculosis Surveillance System Highlights from 2011 National Center for HIV/AIDS, Viral Hepatitis, STD, and.
Orientation on HIV care and ART Recording and Reporting System.
2,500 3,000 3,500 4,000 4,500 5,000 5,500 6,000 2,500 3,000 3,500 4,000 4,500 5,000 5,500 6,000 Figure 1. Number of Tuberculosis Cases: California,
Epidemiologic Studies Consortium Research CTCA meeting October 22, 2010 Lisa Pascopella, PhD, MPH California Department of Health Services.
Preparing for Cohort Review & Standard Forms for Cohort Presentation June 16, 2010 Kieran Hartsough.
TB R&R System's strong points
Number of Tuberculosis Cases: California, Number of Tuberculosis Cases.
California Update : TB Epidemiology and Indicators CTCA October 22, 2010 Jennifer Flood MD MPH Chief, Surveillance and Epidemiology Tuberculosis Control.
1 Identifying Contribution of Community-based DOTS in Treatment Outcome of TB Patients in Four Provinces of Afghanistan Qader, Ghulam MD, DPH, MPH Senior.
Sub module 3 Pre-ART and ART registers. Purpose of registers Key individual information for: Facilitating patient management by the identification of.
Predictors of Failure in Timely TB Treatment Completion, United States Carla Winston,PhD TB PEN Focal Point Open Forum June 5,
Figure 1. Number of Tuberculosis Cases: California, Number of Tuberculosis Cases
ICAP Quarterly Master Slide Set July-September 2007.
LEARNING MODULE TITLE SUBTITLE. HISTORY OF PRESENT ILLNESS An 18 year-old woman with no past medical history and no known risks for TB presents with several.
Taipei, June Content  Introduction about Vietnam’s Programmatic Management of Drug resistant Tuberculosis (PMDT) and drug resistant tuberculosis.
Sarah Al-Obaydi M.B.Ch.B, MPH(c) Fulbright scholar.
A Way out of Directly Observed Therapy (DOT): Community approaches to Self-Administered Treatment for Rifampicin Resistant Tuberculosis in Khayelitsha,
Sashindran V K, Sashwat S, Kumar Suman,
STAND Trial NC-006 (M-Pa-Z) Dr Suzanne Staples Principal Investigator at THINK 26 Mar 2015.
The Ethiopian TB HAART study: Find out the timing for ART when CD4< 200cells/µL Anything new? Wondwossen Amogne, Abiy H/ wold, Getent Yimer,
Palliative Care and M/XDR-TB Global burden of M/XDR-TB
Copyright © 2006 American Medical Association. All rights reserved.
Tolerability of Isoniazid Preventive Therapy (IPT) in an HIV infected cohort
Copyright © 2012 American Medical Association. All rights reserved.
Free State TB Information
Fifth Pacific Stop TB meeting Fiji Islands, May 4-7, 2010
MDR-TB Update Dr Kelvin Charambira
This is an archived document.
Design of a multicohort evaluation of statin adherence after the start of 2 cost-sharing policies Sebastian Schneeweiss, et al. Circulation 2007;115:
TUBERCULOSIS IN VIRGINIA
CommCare as a Tool to Reduce Loss to Follow Up
Dr. Joseph Bana-Koiri Dr. Gilbert Hiawalyer Papua New Guinea
Session 4: Expanded indications for bedaquiline and delamanid
Tolerability of Isoniazid Preventive therapy Among HIV infected Cohort in Nigeria Folajinmi Oluwasina Strategic Information Unit AIDS Healthcare Foundation,
24 July 2018 Treatment outcomes with bedaquiline use when substituted for second-line injectables in multidrug resistant tuberculosis: a retrospective.
Tuberculosis in Wales Annual Report 2018 Data to the end of 2017
National Tuberculosis Control Program Department of Health Philippines Dr. Vivian S. Lofranco Medical Specialist IV.
Cheng shiming National TB Center in China May,3, 2004
Mentoring CHV Supervisors to Ensure Treatment Adherence of TB Patients
TB epidemiology in Bulgaria
Monitoring of Antiretroviral therapy (ART)delivery by Regional Tuberculosis Officers (RTO) in Malawi: Rhehab Chimzizi Anthony Harries Edwin Libamba Maxwell.
Country presentation Dr.Vija Riekstina National TB registry
Surveillance, Monitoring and Evaluation Working Group
Tuberculosis in Wales Annual Report 2017 Data to the end of 2016
Presentation transcript:

New Hampshire Training Cohort Fourth Quarter 2009 Cohort June 16, 2010

Index of Completion as of June 16, 2010

If you exclude those who could not complete by today Index of Completion Goal: 50% If you exclude those who could not complete by today (MDR TB cases)

including those who are likely to complete Index of Completion including those who are likely to complete

Index of Completion excluding MDR TB cases Goal: 90%

Death Rate

Default Rate

Total Cohort Failure Rate

Percentage of Eligible Patients Ever on DOT Goal: 70% Median Months on DOT*: Mean DOT Overall Adherence*: Median DOT Overall Adherence*: *of patients who are on DOT

Timeliness of Patient Interviews

Smear Positive-Interview Trend Sputum Smear + Cases Interviewed within 3 Days Goal: 95%

Contacts Evaluated Goal for contacts to smear + cases: 95%

Contacts Infected Goal: 85%

Contacts Starting on LTBI Treatment

Likely to Complete Cases Treatment Completion First Quarter 2009 62 Cases Counted and started on Treatment Completed at Cohort 44 Likely to Complete Cases 12

Final Completion Results for First Quarter 2009 Goal: 90% Reported Results: 100% Finalized Results: 98% 102243: Pt had extensive disseminated TB and liver failure. Pt completed treatment over 365 days due to intolerance of a standard TB regimen. Meds were on hold and different regimens were tried. Pt was able to tolerate RIF/EMB so the regimen was extended to ensure she received 12 months of actual treatment.

Likely to Complete Vs Completion within 12 months Goal: 90%

New Hampshire Cohort Training First Quarter 2009 Cohort Contacts Started on TLTBI As of June 16, 2010 Goal: 85% completion **Default: Refused, Lost, Moved, Adverse Reaction, TSTNA ***Exclusions: Not Infected, New TB Case, Died Completion = Complete/(Started - Exclusions)*100

LTBI Completion First Quarter 2009 Goal: 85%

Thank you!